Bulk RNA-seq of femoral/tibial bone tissues from OVX-induced osteoporosis mice treated with DCNPs, ALN, Mix, OVX controls or healthy controls.

This dataset contains bulk transcriptome sequencing (RNA-seq) data generated from femur/tibia bone tissues collected in a murine ovariectomy (OVX) osteoporosis model to evaluate the therapeutic effects of dynamic covalent nanoparticles (DCNPs). Five experimental groups were profiled:Healthy (sham) (Labelled NC in data file)OP + PBS (PBS)(Labelled OVX in data file)OP + Alendronate (ALN)(Labelled ALN in data file)OP + Mix (EA + ALN + PEI + CaCl2 without 2-FPBA)(Labelled Mix in data file)OP + DCNPs (EA + ALN + PEI + 2-FPBA + CaCl2) (Labelled NPs in data file)Female C57BL/6J mice were used. The goal is to characterize DCNP-mediated transcriptional reprogramming in bone, including activation of JAK2–STAT3 signaling and suppression of inflammatory lipid metabolism pathways identified in the companion manuscript.ProviderSequencing was performed by Lianchuan Company (commercial service provider).Assay and platformAssay type: Bulk RNA-seq (poly(A)+ selection; stranded library)Platform: Illumina NovaSeq 6000Read configuration: paired-end 2 × 150 bpSamplesSpecies/strain/sex: Mus musculus, C57BL/6J, femaleModel: Ovariectomy (OVX) osteoporosis model; sham for HealthyTissue: Femur and tibia (bone)Groups and size: 5 groups × n = 3 biological replicates per group = 15 libraries totalAge at surgery: 8 weeks; therapy period: 8 weeksTreatments: Healthy; PBS; ALN (1.4 mg/kg/week, IV); Mix (same ALN dose); DCNPs (same ALN dose embedded in DCNPs), twice weekly IV injectionsHarvest: endpoint at week 16Ethics: Approved by the Laboratory Animal Ethics Committee of the First Affiliated Hospital of Wenzhou Medical University (No. WYYY-AEC-2025-008)Data content and organization